Canakinumab + Placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Coronavirus Infection
Conditions
Coronavirus Infection, Diabetes Mellitus, Type 2
Trial Timeline
Oct 23, 2020 → Aug 17, 2021
NCT ID
NCT04510493About Canakinumab + Placebo
Canakinumab + Placebo is a phase 3 stage product being developed by Novartis for Coronavirus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04510493. Target conditions include Coronavirus Infection, Diabetes Mellitus, Type 2.
What happened to similar drugs?
0 of 11 similar drugs in Coronavirus Infection were approved
Approved (0) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05725343 | Phase 3 | Terminated |
| NCT04510493 | Phase 3 | Completed |
| NCT04362813 | Phase 3 | Completed |
| NCT03447769 | Phase 3 | Terminated |
| NCT02059291 | Phase 3 | Completed |
| NCT01390350 | Phase 2 | Completed |
| NCT00889863 | Phase 3 | Completed |
| NCT00886769 | Phase 3 | Terminated |
| NCT00581945 | Phase 1/2 | Completed |
| NCT00424346 | Phase 2 | Completed |
Competing Products
20 competing products in Coronavirus Infection